Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: 5HT2A

or Cathinone

or Opioid

Use the filters below to narrow your results.

Codeine (2)

None (26) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Rexulti (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)

Active metabolite of tramadol; mu-opioid agonist (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Partial mu-opioid agonist; kappa antagonist (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (6) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective mu-opioid receptor agonist (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Ultra-short-acting mu-opioid agonist (1)

None (45) · Mild to moderate pain; cough suppression (low-dose). (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)

None (45) · Adult: 15–60 mg every 4 hours as needed. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)

None (45) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (45) · 360 mg/day (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1)

None (45) · Oral (1) · PO (only formulation marketed in the US). (1)

None (45) · 30–60 min (PO) (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)

None (45) · 4–6 hours (1) · Daily dosing (1)

None (45) · 2.5–3 hours (1) · ~91 hours (1)

None (45) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~95% (1)

None (45) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; National Pregnancy Registry available (1)

None (45) · Rx (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)